|
業務類別
|
Biotechnology |
|
業務概覽
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly knownas VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
| 公司地址
| 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453 |
| 電話號碼
| +1 617 272-4600 |
| 傳真號碼
| +1 617 272-4601 |
| 公司網頁
| https://www.viridiantherapeutics.com |
| 員工數量
| 252 |
| Dr. Radhika Tripuraneni, M.D.,M.P.H. |
Chief Medical Officer |
-- |
25/04/2025 |
| Mr. Seth Harmon |
Chief Financial Officer and Principal Accounting Officer |
美元 419.60K |
26/02/2026 |
| Ms. Jennifer Tousignant |
Chief Legal Officer |
美元 400.57K |
25/04/2025 |
| Mr. Stephen Mahoney |
President, Chief Executive Officer and Director |
美元 650.00K |
26/02/2026 |
| Mr. Thomas W. Beetham |
Chief Operating Officer |
美元 500.00K |
25/04/2025 |
|
|
| Ms. Arlene M. Morris |
Independent Director |
26/02/2026 |
| Mr. Jeffrey R. Ajer |
Director |
26/02/2026 |
| Ms. Jennifer K. Moses |
Independent Director |
26/02/2026 |
| Dr. Christopher Cain, PhD |
Director |
26/02/2026 |
| Mr. Tomas Kiselak |
Chairman of the Board |
26/02/2026 |
| Dr. Sarah Gheuens, M.D.,PhD |
Independent Director |
26/02/2026 |
| Mr. Stephen Mahoney |
President, Chief Executive Officer and Director |
26/02/2026 |
|
|
|
|
